Physical and functional interaction of the TPL2 kinase with nucleophosmin

被引:0
|
作者
D C Kanellis
S Bursac
P N Tsichlis
S Volarevic
A G Eliopoulos
机构
[1] Molecular and Cellular Biology Laboratory,Division of Basic Sciences
[2] University of Crete Medical School,Department of Molecular Medicine and Biotechnology
[3] Laboratory of Cancer Biology,undefined
[4] Institute of Molecular Biology and Biotechnology,undefined
[5] Foundation for Research and Technology Hellas (FORTH),undefined
[6] School of Medicine,undefined
[7] University of Rijeka,undefined
[8] Molecular Oncology Research Institute,undefined
[9] Tufts Medical Center,undefined
来源
Oncogene | 2015年 / 34卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tumor Progression Locus 2 (TPL2) is widely recognized as a cytoplasmic mitogen-activated protein 3 kinase with a prominent role in the regulation of inflammatory and oncogenic signal transduction. Herein we report that TPL2 may also operate in the nucleus as a physical and functional partner of nucleophosmin (NPM/B23), a major nucleolar phosphoprotein with diverse cellular activities linked to malignancy. We demonstrate that TPL2 mediates the phosphorylation of a fraction of NPM at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state NPM levels. Upon exposure to ultraviolet C, Tpl2 is required for the translocation of de-phosphorylated NPM from the nucleolus to the nucleoplasm. NPM is an endogenous inhibitor of HDM2:p53 interaction and knockdown of TPL2 was found to result in reduced binding of NPM to HDM2, with concomitant defects in p53 accumulation following genotoxic or ribosomal stress. These findings expand our understanding of the function of TPL2 as a negative regulator of carcinogenesis by defining a nuclear role for this kinase in the topological sequestration of NPM, linking p53 signaling to the generation of threonine 199-phosphorylated NPM.
引用
收藏
页码:2516 / 2526
页数:10
相关论文
共 50 条
  • [1] Physical and functional interaction of the TPL2 kinase with nucleophosmin
    Kanellis, D. C.
    Bursac, S.
    Tsichlis, P. N.
    Volarevic, S.
    Eliopoulos, A. G.
    ONCOGENE, 2015, 34 (19) : 2516 - 2526
  • [2] Discovery of indazoles as inhibitors of Tpl2 kinase
    Hu, Yonghan
    Cole, Derek
    Denny, Rajiah
    Anderson, David
    Ipek, Manus
    Ni, Yike
    Thaisrivongs, Suvit
    Wang, Xiaolun
    Hall, J. Perry
    Liu, Julie
    Luong, Michael
    Lin, Lih-Ling
    Telliez, Jean-Baptiste
    Gopalsamy, Ariamala
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [3] TPL2 kinase is a suppressor of lung carcinogenesis
    Eliopoulos, A.
    FEBS JOURNAL, 2014, 281 : 37 - 37
  • [4] Discovery of indazoles as inhibitors of Tpl2 kinase
    Hu, Yonghan
    Cole, Derek
    Denny, Rajiah Aldrin
    Anderson, David R.
    Ipek, Manus
    Ni, Yike
    Wang, Xiaolun
    Thaisrivongs, Suvit
    Chamberlain, Timothy
    Hall, J. Perry
    Liu, Julie
    Luong, Michael
    Lin, Lih-Ling
    Telliez, Jean-Baptiste
    Gopalsamy, Ariamala
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (16) : 4758 - 4761
  • [5] TPL2 kinase is a suppressor of lung carcinogenesis
    Gkirtzimanaki, Katerina
    Gkouskou, Kalliopi K.
    Oleksiewicz, Urszula
    Nikolaidis, Georgios
    Vyrla, Dimitra
    Liontos, Michalis
    Pelekanou, Vassiliki
    Kanellis, Dimitris C.
    Evangelou, Kostantinos
    Stathopoulos, Efstathios N.
    Field, John K.
    Tsichlis, Philip N.
    Gorgoulis, Vassilis
    Liloglou, Triantafillos
    Eliopoulos, Aristides G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (16) : E1470 - E1479
  • [6] TPL2 kinase action and control of inflammation
    Xu, Daqi
    Kwon, Youngsu
    Senger, Kate
    Pham, Victoria
    Varfolomeev, Eugene
    Francis, George
    Hackney, Jason
    Parr, Brendan
    Rathore, Nisha
    Setiadi, Francesca
    Boenig, Gladys
    Harris, Seth
    Lupardus, Patrick
    Matsumoto, Marissa
    Wang, Yuanyuan
    Hanson, Jesse
    Maher, Jonathan
    Wu, Kai
    Shaw, Andrey
    Scherl, Alexis
    Wu, Jiansheng
    Lu, Cheng
    Huang, Zhiyu
    Zhang, Juan
    Park, Summer
    Sujatha-Bhaskar, Swathi
    Almazan, Alice
    Xu, Min
    Caplazi, Patrick
    Brightbill, Hans
    Ghilardi, Nico
    Townsend, Michael
    Lee, Wyne
    Johnson, Adam
    McKenzie, Brent
    Zarrin, Ali A.
    Wilson, Mark
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [7] TPL2 kinase action and control of inflammation
    Xu, Daqi
    Matsumoto, Marissa L.
    McKenzie, Brent S.
    Zarrin, Ali A.
    PHARMACOLOGICAL RESEARCH, 2018, 129 : 188 - 193
  • [8] Tpl2 kinase regulates inflammation but not tumorigenesis in mice
    Wu, Kai Connie
    Cain, Gary
    Corpuz, Janice
    Xu, Daqi
    Ljumanovic, Nina
    Zarrin, Ali A.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 418
  • [9] TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Hope, Chelsea
    Ollar, Samuel J.
    Heninger, Erika
    Jensen, Jeffrey L.
    Hebron, Ellen
    Kim, Jaehyup
    Maroulakou, Ioanna
    Miyamoto, Shigeki
    Callander, Natalie
    Hematti, Peiman
    Chesi, Marta
    Bergsagel, P. Leif
    Asimakopoulos, Fotis
    CANCER RESEARCH, 2014, 74 (19)
  • [10] TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Hope, Chelsea
    Ollar, Samuel J.
    Heninger, Erika
    Hebron, Ellen
    Jensen, Jeffrey L.
    Kim, Jaehyup
    Maroulakou, Ioanna
    Miyamoto, Shigeki
    Leith, Catherine
    Yang, David T.
    Callander, Natalie
    Hematti, Peiman
    Chesi, Marta
    Bergsagel, P. Leif
    Asimakopoulos, Fotis
    BLOOD, 2014, 123 (21) : 3305 - 3315